WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved the kinase inhibitor KOSELUGO™ (selumetinib) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
PMC Isochem invests 2 Millions € in R&D
PALM BEACH, Florida, Nov. 6, 2019 /PRNewswire/ -- Because almost every new projection for the global cannabis markets shows revenues continuing to rise together with an increasing growth rate, the recreational cannabis market has captured most of the media's attention, but there are other uses of the plant that are just as lucrative for companies. Medical cannabis is the other half of the industry that, although just as profitable, doesn't get as much coverage as the recreational side. Over the years, we've seen this sector grow from doctors prescribing marijuana to patients for pain symptoms all the way to sophisticated biotech and pharmaceutical companies developing new drugs to treat conditions like childhood epilepsy.
TECLens and SERVImed Industrial Spa Announce a Partnership to Pursue U.S. FDA Approval for Trans-epithelial Corneal Cross-Linking
Vinorelbine Bitartrate (VRL), a semi-synthetic vinca alkaloid was approved by the FDA for breast cancer treatment, as it has been proven to be beneficial for first line of defense and subsequent therapies. But its hydrophilic and thermolabile structure causes hindrance to oral clinical translation. The main objective of this research is the development and optimization of a solid lipid nanoparticle (SLN) structure that can encapsulate hydrophilic and thermolabile Vinorelbine bitartrate to maximize the anticancer activity of the drug without compromising its efficacy and integrity. For this purpose, the study is mainly focused on the application of DOE, a modern statistical optimization tool for nanoparticle modification.
Access to high-throughput synthesis and screening technologies has enabled the discovery of novel classes of small molecules that exhibit high potency. Unfortunately, many of these compounds suffer from poor solubility and bioavailability when administered in conventional solid-dosage forms, the preferred route of administration due to convenience and ease of use. Formulation as amorphous solid dispersions (ASDs)--most commonly via spray drying (SD) or hot-melt extrusion (HME) and more recently co-precipitation (CP)--is increasingly used to improve the performance of poorly soluble drugs. The choice of excipients for spray-dried formulations has a direct impact on the stability and efficacy of these ASDs.
Fine chemicals and active ingredients specialist CMO Isochem will field a strong suite of attractions when it exhibits at CPhI Worldwide in Barcelona in October.nIn particular, Isochem will be able to present visitors to its stand 3A78in Hall 3 at Fira de Barcelona, with a whole portfolio of impressive capabilities.